Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EAPB0503: An Imiquimod analog with potent in vitro activity against cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica
Rana El Hajj, Hanady Bou Youness, Laurence Lachaud, et al.
PLoS neglected tropical diseases (2018) Vol. 12, Iss. 11, pp. e0006854-e0006854
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes
Cindy Patinote, Nour Bou Karroum, Georges Moarbess, et al.
European Journal of Medicinal Chemistry (2020) Vol. 193, pp. 112238-112238
Open Access | Times Cited: 95
4-Aminoquinoline as a privileged scaffold for the design of leishmanicidal agents: structure–property relationships and key biological targets
Angel H. Romero, Francisco Delgado
Frontiers in Chemistry (2025) Vol. 12
Open Access | Times Cited: 1
Leishmaniasis immunopathology—impact on design and use of vaccines, diagnostics and drugs
Paul M. Kaye, Israel Cruz, Albert Picado, et al.
Seminars in Immunopathology (2020) Vol. 42, Iss. 3, pp. 247-264
Open Access | Times Cited: 66
Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight
Humzah Jamshaid, Fakhar ud Din, Gul Majid Khan
Journal of Nanobiotechnology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 53
Protective or Detrimental? Understanding the Role of Host Immunity in Leishmaniasis
Camila dos Santos Meira, Lashitew Gedamu
Microorganisms (2019) Vol. 7, Iss. 12, pp. 695-695
Open Access | Times Cited: 49
An overview of the treatment of cutaneous leishmaniasis
Talissa Fernanda Garza-Tovar, Marco I Sacriste-Hernández, Eder Rodrigo Juárez-Durán, et al.
Faculty Reviews (2020) Vol. 9
Open Access | Times Cited: 48
Toxoplasmosis: Current and Emerging Parasite Druggable Targets
Rana El Hajj, Lina Tawk, Shaymaa Itani, et al.
Microorganisms (2021) Vol. 9, Iss. 12, pp. 2531-2531
Open Access | Times Cited: 33
Evaluation of Immunopharmacological efficacy of live Leishmania donovani overexpressing Ld_ζ1domain for protection against experimental human visceral Leishmaniasis.
Ruby Bansal, Sadat Shafi, Prachi Garg, et al.
International Immunopharmacology (2025) Vol. 151, pp. 114295-114295
Open Access
Leishmaniases: Strategies in treatment development.
Alissa Majoor, Grégory Michel, Pierre Marty, et al.
PubMed (2025) Vol. 32, pp. 18-18
Closed Access
Current status of quinoxaline and quinoxaline 1,4‐di‐N‐oxides derivatives as potential antiparasitic agents
Jacqueline Soto‐Sánchez, Juan David Ospina‐Villa
Chemical Biology & Drug Design (2021) Vol. 98, Iss. 4, pp. 683-699
Closed Access | Times Cited: 22
Mannosylated imiquimod-terbinafine co-loaded transethosomes for cutaneous leishmaniasis; assessment of its anti-leishmanial potential, in vivo safety and immune response modulation
Humzah Jamshaid, Fakhar ud Din, Kainat Nousheen, et al.
Biomaterials Advances (2022) Vol. 145, pp. 213266-213266
Closed Access | Times Cited: 14
The characterization of toll‐like receptor repertoire in Pinna nobilis after mass mortality events suggests adaptive introgression
Stéphane Coupé, Ioannis Α. Giantsis, Maite Vázquez‐Luis, et al.
Ecology and Evolution (2023) Vol. 13, Iss. 8
Open Access | Times Cited: 8
Successful treatment of chromoblastomycosis caused by Fonsecaea pedrosoi using imiquimod
Walter Belda, Paulo Ricardo Criado, Luiz Felipe Domingues Passero
The Journal of Dermatology (2020) Vol. 47, Iss. 4, pp. 409-412
Closed Access | Times Cited: 22
Exploring Innovative Leishmaniasis Treatment: Drug Targets from Pre‐Clinical to Clinical Findings
Wanessa Santana, Simone S. C. Oliveira, Mariana H. Ramos, et al.
Chemistry & Biodiversity (2021) Vol. 18, Iss. 9
Open Access | Times Cited: 19
Targeting and activation of macrophages in leishmaniasis. A focus on iron oxide nanoparticles
Carmen Palomino-Cano, Esther Moreno, Juan M. Irache, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Expanded genome-wide comparisons give novel insights into population structure and genetic heterogeneity of Leishmania tropica complex
Tamara Salloum, Rim Moussa, Ryan Rahy, et al.
PLoS neglected tropical diseases (2020) Vol. 14, Iss. 9, pp. e0008684-e0008684
Open Access | Times Cited: 20
Imiquimod Targets Toxoplasmosis Through Modulating Host Toll-Like Receptor-MyD88 Signaling
Maguy Hamie, Rania Najm, Carine Deleuze‐Masquéfa, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 13
Impregnated Nanofibrous Mat with Nanogel of Citrus sinensis Essential Oil as a New Type of Dressing in Cutaneous Leishmaniasis
Ali Ghanbariasad, Fatemeh Amoozegar, Mahya Rahmani, et al.
Biointerface Research in Applied Chemistry (2020) Vol. 11, Iss. 4, pp. 11066-11076
Open Access | Times Cited: 13
Toll-like receptor-7/8 agonist kill Leishmania amazonensis by acting as pro-oxidant and pro-inflammatory agent
Deepender Kaushik, Juliana T. Granato, Gilson Costa Macedo, et al.
Journal of Pharmacy and Pharmacology (2021) Vol. 73, Iss. 9, pp. 1180-1190
Open Access | Times Cited: 11
Managing chromoblastomycosis with acitretin plus imiquimod: A case report on the improvement of cutaneous lesions and reduction of the treatment time
Walter Belda, Ana Thereza Stradioto Casolato, Juliana Bronzato Luppi, et al.
The Journal of Dermatology (2021) Vol. 48, Iss. 10, pp. 1612-1615
Closed Access | Times Cited: 10
Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis
Philippe M. Loiseau, Sébastien Pomel, Simon L. Croft
Molecules (2020) Vol. 25, Iss. 18, pp. 4123-4123
Open Access | Times Cited: 10
Efficacy of imiquimod 5% cream as first-line management in cutaneous leishmaniasis caused by Leishmania mexicana
Gabriela Fuentes-Nava, Andrés Tirado‐Sánchez, Edith A. Fernández-Figueroa, et al.
Revista da Sociedade Brasileira de Medicina Tropical (2021) Vol. 54
Open Access | Times Cited: 8
Biological applications of imiquimod analogues: An update (Review)
Joëlle Obeid, Abdullah Shaito, Hiba El Hajj, et al.
World Academy of Sciences Journal (2023) Vol. 5, Iss. 3
Open Access | Times Cited: 3
HAS 1: A natural product from soil-isolated Streptomyces species with potent activity against cutaneous leishmaniasis caused by Leishmania tropica
Bassel Awada, Maguy Hamie, Rana El Hajj, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 5
High Content Analysis of Macrophage-Targeting EhPIb-Compounds against Cutaneous and Visceral Leishmania Species
Helena Fehling, Hanno Niss, Annika Bea, et al.
Microorganisms (2021) Vol. 9, Iss. 2, pp. 422-422
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top